103 related articles for article (PubMed ID: 30535474)
1. Association between interleukin‑33 and ovarian cancer.
Liu X; Hansen DM; Timko NJ; Zhu Z; Ames A; Qin C; Nicholl MB; Bai Q; Chen X; Wakefield MR; West G; Fang Y
Oncol Rep; 2019 Feb; 41(2):1045-1050. PubMed ID: 30535474
[TBL] [Abstract][Full Text] [Related]
2. Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
Sekiya A; Suzuki S; Tanaka A; Hattori S; Shimizu Y; Yoshikawa N; Koya Y; Kajiyama H; Kikkawa F
Int J Oncol; 2019 Sep; 55(3):755-765. PubMed ID: 31322193
[TBL] [Abstract][Full Text] [Related]
3. IL‑33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway.
Zhang JF; Wang P; Yan YJ; Li Y; Guan MW; Yu JJ; Wang XD
Oncol Rep; 2017 Oct; 38(4):2033-2042. PubMed ID: 28849217
[TBL] [Abstract][Full Text] [Related]
4. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
Tanaka R; Tomosugi M; Horinaka M; Sowa Y; Sakai T
PLoS One; 2015; 10(5):e0125779. PubMed ID: 25955843
[TBL] [Abstract][Full Text] [Related]
5. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.
Goyeneche AA; Carón RW; Telleria CM
Clin Cancer Res; 2007 Jun; 13(11):3370-9. PubMed ID: 17545545
[TBL] [Abstract][Full Text] [Related]
6. IL-39 acts as a friend to pancreatic cancer.
Manning AA; Zhao L; Zhu Z; Xiao H; Redington CG; Ding VA; Stewart-Hester T; Bai Q; Dunlap J; Wakefield MR; Fang Y
Med Oncol; 2018 Dec; 36(1):12. PubMed ID: 30506430
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner.
Eissmann MF; Dijkstra C; Wouters MA; Baloyan D; Mouradov D; Nguyen PM; Davalos-Salas M; Putoczki TL; Sieber OM; Mariadason JM; Ernst M; Masson F
Cancer Immunol Res; 2018 Apr; 6(4):409-421. PubMed ID: 29463593
[TBL] [Abstract][Full Text] [Related]
8. CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.
Lee JC; Chou LC; Huang CH; Chung JG; Huang LJ; Lee KH; Hung MC; Way TD; Kuo SC
Eur J Pharmacol; 2011 Nov; 670(1):96-104. PubMed ID: 21907193
[TBL] [Abstract][Full Text] [Related]
9. Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts.
Nishida A; Andoh A; Imaeda H; Inatomi O; Shiomi H; Fujiyama Y
Gut; 2010 Apr; 59(4):531-41. PubMed ID: 19996325
[TBL] [Abstract][Full Text] [Related]
10. IL‑33 restricts invasion and adhesion of trophoblast cell line JEG3 by downregulation of integrin α4β1 and CD62L.
Wang XH; Liu W; Fan DX; Hu WT; Li MQ; Zhu XY; Jin LP
Mol Med Rep; 2017 Oct; 16(4):3887-3893. PubMed ID: 28765940
[TBL] [Abstract][Full Text] [Related]
11. IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.
Fang M; Li Y; Huang K; Qi S; Zhang J; Zgodzinski W; Majewski M; Wallner G; Gozdz S; Macek P; Kowalik A; Pasiarski M; Grywalska E; Vatan L; Nagarsheth N; Li W; Zhao L; Kryczek I; Wang G; Wang Z; Zou W; Wang L
Cancer Res; 2017 May; 77(10):2735-2745. PubMed ID: 28249897
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
[TBL] [Abstract][Full Text] [Related]
13. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
14. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
Zhao Z; Li C; Xi H; Gao Y; Xu D
Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
[TBL] [Abstract][Full Text] [Related]
15. Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1.
Ha JL; Kaser E; Guan T; Mayberry TG; Smith LA; D'mello K; Bai Q; Wakefield MR; Dong L; Fang Y
Med Oncol; 2024 Jan; 41(3):65. PubMed ID: 38281234
[TBL] [Abstract][Full Text] [Related]
16. IL33 Is a Key Driver of Treatment Resistance of Cancer.
Kudo-Saito C; Miyamoto T; Imazeki H; Shoji H; Aoki K; Boku N
Cancer Res; 2020 May; 80(10):1981-1990. PubMed ID: 32156776
[TBL] [Abstract][Full Text] [Related]
17.
Zhu Z; Zhao L; Brittingham A; Bai Q; Wakefield MR; Fang Y
Anticancer Res; 2018 Sep; 38(9):5079-5086. PubMed ID: 30194152
[TBL] [Abstract][Full Text] [Related]
18. Potential use of kiwifruit extract for treatment of melanoma.
Kou L; Zhu Z; Redington C; Bai Q; Wakefield M; Lequio M; Fang Y
Med Oncol; 2021 Feb; 38(3):25. PubMed ID: 33586074
[TBL] [Abstract][Full Text] [Related]
19. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
20. FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.
Huang Y; Jin H; Liu Y; Zhou J; Ding J; Cheng KW; Yu Y; Feng Y
Endocr Relat Cancer; 2011 Feb; 18(1):13-26. PubMed ID: 20943720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
